Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8158

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more

Conditions: Hypercholesterolaemia
Interventions: Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 77
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more

Conditions: Heart Failure
Interventions: Finerenone, Empagliflozin; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more

Conditions: Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions: ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham; Drug · Other
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 56
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions: Bemarituzumab, Nivolumab, Chemotherapy, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Cerritos, California • Downey, California + 31 more

Conditions: Recurrent Pericarditis
Interventions: CardiolRx; Drug
Lead sponsor: Cardiol Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more

Conditions: Lennox Gastaut Syndrome (LGS)
Interventions: Placebo, Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery; Procedure · Other · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 208
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more

Conditions: Marburg Virus Disease
Interventions: cAd3-Marburg Vaccine, Placebo; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more

Conditions: Opioid Use Disorder
Interventions: Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 25
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Congenital Heart Disease (CHD)
Interventions: HeartGPS; Other
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 13 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

A Study of Mosliciguat in PH-ILD

Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)